Employers expect health‑care costs to jump 9.2% in 2027, a rise that analysts say will increasingly squeeze household budgets through lower wage growth or higher employee contributions to insurance, according to a recent industry survey.
Drivers of the rise
The projection, published by the Business Group on Health and reported to NewsNation, continues a pattern in which actual health‑care spending has outpaced earlier forecasts. Employers are confronting multiple cost pressures, including rising prescription costs and greater utilisation of services. The report also highlights the role of new technologies such as artificial intelligence, which, while promising improvements in care, can be associated with higher charges in some settings.
Industry commentators point to the shifting composition of health spending within employer plans. Pharmacy costs have become a disproportionately large component, accounting for 25% of total health‑care spend among employer‑sponsored plans in the United States, the survey’s respondents said.
“When you take a look at health care spend across the board, the second‑highest line item has become pharmacy spend, with 25% of all health care spend happening in the pharmacy space,”
The remark above came from Otto Graham, vice‑president of SHARx Sourcing and Rx Relations. He told NewsNation that rising drug prices and increased utilisation are key drivers behind the upward pressure on employer costs.
Potential impact on workers
Analysts warn that sustained increases in employer health costs can manifest in ways that reduce workers’ real incomes. Employers faced with higher benefit bills may respond by:
- shifting a greater share of premiums, deductibles, copayments or coinsurance onto employees;
- limiting wage growth or pausing pay rises to offset benefit cost growth;
- changing plan designs to steer employees to lower‑cost care or formulary changes affecting drug access.
Federal data cited in the report show that Americans are already paying more out of pocket for deductibles, copays and coinsurance, though the analysis did not provide EU or UK comparators. The survey also estimated that in 2026, people with employer‑sponsored insurance in the United States were expected to spend nearly $5,300 on health care, an increase of $388 from the previous year.
Transparency and procurement suggested as partial fixes
Commentators and employer groups argue that better transparency in pricing and more strategic procurement could moderate cost growth. Graham told reporters that employers will need a clearer picture of where funds are spent and more effective purchasing strategies to obtain efficient prices for care and medicines.
He said employers are increasingly looking for solutions that identify the highest‑value services and negotiate or steer employees toward them. The report did not, however, quantify the potential savings from such strategies or the timeline for any impact on premiums or wages.
Data at a glance
| Metric | Value (from report) |
|---|---|
| Projected employer health‑care cost increase (2027) | 9.2% |
| Share of spend on pharmacy | 25% |
| Average expected spend per person with employer coverage (2026) | $5,300 (up $388 year‑on‑year) |
Limits of the data and wider context
While the figures in the report signal important trends, they are projections and reflect the perspectives of employer groups rather than direct measures of national spending. Projections do not establish causation; higher utilisation and the adoption of new technologies are associated with cost increases, but the precise contribution of any single factor — for example, AI deployment versus drug price inflation — is not quantified in the source material.
Furthermore, the figures relate primarily to the US employer‑sponsored market. Health insurance arrangements, pricing frameworks and regulation differ across countries, so the direct implications for workers in the UK or elsewhere require careful adjustment for local systems. Nonetheless, the underlying dynamics — rising pharmacy costs, greater use of advanced technologies and the potential for costs to be passed to employees — are relevant to employers and policymakers globally.
Policymakers and employers face trade‑offs between maintaining access to new treatments and managing affordability. As employers seek transparency and better procurement, workers and regulators will be watching for whether these measures translate into lower out‑of‑pocket costs or stabilised premiums.
